Forecast Of The First Quarter Report Of The Science And Technology Innovation Board

On April 19, the science and technology innovation board company hot landscape Biology (688068. SH) recorded its fifth consecutive limit, which was 144.41 yuan, up 390% compared with the issue price of 29.46 yuan.

The reason why hot scene is sought after by the secondary market is mainly due to its high performance. On the evening of April 12, the company disclosed the performance forecast for the first quarter of this year, showing that the net profit attributable to the parent company was 560 million yuan to 660 million yuan, with a year-on-year increase of 109125.67% - 128630.25%. More than 1000 times of performance growth, directly led to the next day hot scene biological "five Board" market start.

The 21st century economic reporter combed the first quarter performance forecast of the science and technology innovation board, and found that the growth rate of the above-mentioned profits made by hot scene biology ranked first in the board, and its performance in the biomedical sector was also generally good. At the same time, consumer electronics industry chain companies benefited from the growth of downstream demand, and related stocks also achieved brilliant results in the first quarter.

On the whole, there are 42 companies that have published the first quarter performance forecast on the science and technology innovation board, of which 38 enterprises have announced the specific performance growth rate, of which only 3 enterprises have shown a decline in performance, with the median performance growth rate of about 98.33%, and the overall performance is good.

Recently, the liquidity of the science and technology innovation board has been repeatedly concerned by the market, from the transaction to the change of market value, which has triggered the voice of discussion. However, from the current situation, under the catalysis of the first quarter's performance, the relevant stocks still show obvious activity.

"Kechuang board shares have a high beta attribute, which will lead to a significant reduction in liquidity when the market is relatively weak. At present, the market's pessimism is fully vented, and the upper risk is gradually digested. At the same time, there are certain positive expectations in the peripheral environment, and the market risk preference is expected to increase. In a relatively stable market environment, if the first quarter performance of the science and Technology Innovation Board continues to shine, it will attract incremental funds and drive the plate to rebound. " On April 19, Yin Yue, chief market analyst of YueKai Securities Research Institute, pointed out in an interview.

In 2021, as the overseas epidemic situation has not been effectively controlled, relevant companies continue the performance trend of last year. Xinhua News Agency

Hot scenery creatures win the "pre increase king"

Among the 42 science and Technology Innovation Board companies that have announced the first quarter report forecast, although there are also several times the number of shares in advance, redview still has a 1000 fold increase in net profit, leaving other companies far behind.

Hot scene is a biological high-tech enterprise engaged in R & D, production and sales of in vitro diagnostic reagents and instruments. Its core business, IVD (in vitro diagnosis), is a branch of the medical device industry. During the outbreak, in vitro diagnosis was a means to detect new coronavirus, which benefited hot spot, while the growth in the first quarter of this year was mainly due to its overseas business.

The company said that in the first quarter, two new rapid detection reagents for coronavirus antigen were certified by the German Federal Institute of drugs and medical devices for free detection at home on March 2 and 22, respectively, which led to the explosive growth of foreign trade orders of the company.

It should be noted that the explosive growth of hot scene's performance is also due to the low base of last year. It said that in the first quarter of 2020, affected by the normal business cycle and the epidemic situation, the company's operating performance was small.

In fact, according to the forecast of 2020 annual report disclosed by hot landscape, the annual net profit is only about 110 million yuan. In other words, in the first quarter of this year, the company achieved five times the net profit of last year.

According to our reporter's previous statistics, the performance of some testing reagents, testing instruments and other medical device companies on the science and technology innovation board has experienced explosive growth last year. Among them, 5 IVD companies achieved a total net profit increase of 2020%.

In 2021, as the overseas epidemic situation has not been effectively controlled, relevant companies continue the performance trend of last year. In addition to hot spot, another nucleic acid detection leader, Shengxiang Biology (688289. SH), is expected to achieve a net profit of about 600 million to 650 million yuan in the first quarter, with a year-on-year increase of 210.76% - 236.66%.

The reporter found that among the reasons for the performance growth, Shengxiang biological also specially mentioned the contribution of overseas business to the performance: during the reporting period, the company's overseas sales revenue was 460 million yuan, an increase of 613.34% over the same period.

Guotai Junan Securities research report pointed out that by the end of 2020, the country had exported 1.08 billion copies of Xinguan detection reagents (nucleic acid + antigen antibody), with an estimated revenue of about 5 billion US dollars. China's IVD export accounted for a relatively low proportion in the world. With the help of Xinguan, many companies quickly set up overseas channels, laying a foundation for subsequent product export.

In the biomedical sector, most of the companies that have announced their performance have achieved rapid growth: Kemei diagnostics (688468. SH), which is engaged in clinical immunochemiluminescence diagnosis and detection, is expected to grow by 271% - 327% in the first quarter of this year, Xiangyu medical (688626. SH), which is mainly engaged in rehabilitation physiotherapy equipment, is expected to increase by 51.57%, and Aotai bio (688606. SH), which mainly focuses on in vitro diagnostic reagents, is expected to grow by 234.71%, Haohaishengke (688366. SH), which is mainly engaged in medical absorbable biomaterials, also made a profit. Only Sinochem (688108. SH) had a net profit loss of 41.29 million yuan, which was affected by the national policy of centralized collection of coronary stents.

Consumer electronics demand growth favors upstream

In addition to the biomedical sector, the industries with reference significance in the performance forecast of the science and technology innovation board (the total number of stocks is more than 5, the number of shares disclosed is more than 2, and the disclosure rate is more than 10%), as well as the mechanical equipment, chemical industry, national defense and military industry, electronic and electrical equipment industries, which maintain a relatively high overall prosperity. Among them, the industries with more than 100% median performance are national defense and military industry (484.78%), medical biology (234.71%), mechanical equipment (135.83%) and chemical industry (100.65%). The median performance growth rates of electrical equipment and electronics are 45.58% and 33.53% respectively.

It is worth mentioning that since last year, the chip shortage has swept the world, and the growth of downstream demand has driven the performance of related industry chain companies to rise sharply, which is also reflected in the relevant science and Technology Innovation Board companies.

Among them, it is remarkable that Sifang Optoelectronics (688665. SH), whose main business is gas sensors, is expected to achieve a net profit of about 31 million yuan to 33 million yuan, with a year-on-year growth of 7567.57% - 8062.26%, which is second only to hot prospect.

A typical example is jept (688025. SH), whose main product is optoelectronic components. It is expected to achieve a net profit of about 20 million yuan - 24.5 million yuan in the first quarter, with an increase of 186.48% - 250.93%. In the first quarter, the demand for pulsed high-power fiber lasers in the consumer electronics industry, photovoltaic industry and laser cleaning industry increased significantly, the company said. Since the second half of 2020, the global demand for resistance has increased, and manufacturers of passive components all over the world are actively expanding their production. The company's orders for resistor adjusting machines have achieved a significant year-on-year growth. The relocation of relevant production lines of the company has increased the production capacity.

Songjing Co., Ltd. (688157. SH) is a coating manufacturer and a supplier of several well-known consumer electronics brands. Its net profit is expected to increase by 50% - 65% in the first quarter.

With the recovery of the prosperity of the downstream high-end consumer electronics industry, Matsui's share of coating products in important end customers such as Xiaomi, North American consumer electronics customers, HP and other important end customers has been further increased. The impact of the successive release of new products such as wearable devices, HP laptops and accessories has driven the company's business revenue growth.

"From the current industry growth situation, high growth industries are mainly concentrated in Pro cyclical industries. On the one hand, these industries benefit from the demand recovery brought by the sustained economic recovery, on the other hand, they also benefit from the rising volume and price brought by the upward industrial cycle. For a period of time in the future, it will be the intensive disclosure period of the first quarter performance of the science and technology innovation board, so we can focus on the certainty of such high growth For higher procyclical industries. " Yin Yue said.

It should be pointed out that although the above companies' performance growth is gratifying, we should also be alert to "data illusion". Not only hot scene, but also jept, Sifang optoelectronics and other companies mentioned that, affected by the epidemic, the company's performance in the first quarter of 2020 was lower than the average level of the company in previous years, resulting in a small base compared with the first quarter of 2021, which resulted in a high growth in the first quarter of this year.

?